These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24360324)

  • 1. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
    Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
    J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
    Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
    Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of a bullous urticaria with omalizumab.
    Ozturk AB; Kocaturk E; Ozturk E
    Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
    Wu KCP; Jabbar-Lopez ZK
    J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab is effective in nonautoimmune urticaria.
    Ferrer M; Gamboa P; Sanz ML; Goikoetxea MJ; Cabrera-Freitag P; Javaloyes G; Berroa F; Kaplan AP
    J Allergy Clin Immunol; 2011 May; 127(5):1300-2. PubMed ID: 21315432
    [No Abstract]   [Full Text] [Related]  

  • 7. Extraordinary response to omalizumab in a child with severe chronic urticaria.
    Asero R; Casalone R; Iemoli E
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):41-2. PubMed ID: 24702874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
    J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life experiences with omalizumab for the treatment of chronic urticaria.
    Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light.
    Duchini G; Bäumler W; Bircher AJ; Scherer K
    Photodermatol Photoimmunol Photomed; 2011 Dec; 27(6):336-7. PubMed ID: 22092741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
    Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
    Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
    Wieder S; Maurer M; Lebwohl M
    Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
    Kaplan A; Ledford D; Ashby M; Canvin J; Zazzali JL; Conner E; Veith J; Kamath N; Staubach P; Jakob T; Stirling RG; Kuna P; Berger W; Maurer M; Rosén K
    J Allergy Clin Immunol; 2013 Jul; 132(1):101-9. PubMed ID: 23810097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the spectrum: chronic urticaria and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
    Lundberg C; Martinez B; Banks TA
    Ann Allergy Asthma Immunol; 2015 Apr; 114(4):353-4. PubMed ID: 25707324
    [No Abstract]   [Full Text] [Related]  

  • 16. Omalizumab in chronic urticaria: a retrospective series of 15 cases.
    Armengot-Carbo M; Velasco-Pastor M; Rodrigo-Nicolas B; Pont-Sanjuan V; Quecedo-Estebanez E; Gimeno-Carpio E
    Dermatol Ther; 2013; 26(3):257-9. PubMed ID: 23742285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab. An option in vernal keratoconjunctivitis?
    Sánchez J; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):319-20. PubMed ID: 21975146
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab for chronic urticaria.
    Casale TB
    J Allergy Clin Immunol Pract; 2014; 2(1):118-9. PubMed ID: 24565785
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?
    Tontini C; Marinangeli L; Cognigni M; Bilò MB; Antonicelli L
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):147-8. PubMed ID: 26048249
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of omalizumab in a patient with three types of chronic urticaria.
    Vieira Dos Santos R; Locks Bidese B; Rabello de Souza J; Maurer M
    Br J Dermatol; 2014 Feb; 170(2):469-71. PubMed ID: 24102388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.